SEC Form 4 · accession 0001209191-18-043906
Cue Biopharma, Inc. · CUE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ronald D. Seidel III
Officer — EVP, Head of R&D
Period of report
Jul 23, 2018
Accepted (ET)
Jul 25, 2018 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001645460
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $11.54 | Jul 23, 2018 | A | 75,000 | A | — | Jul 23, 2025 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1This stock option grant becomes exercisable in eight semi-annual installments beginning July 23, 2018.